SEC Filings

Form 10-Q
NEUROCRINE BIOSCIENCES INC filed this Form 10-Q on 11/05/2018
Document Outline
Entire Document (4957.7 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - NEUROCRINE BIOSCIENCES, INC.
Page 3 - PART I. FINANCIAL INFORMATION
Page 4 - NEUROCRINE BIOSCIENCES, INC.
Page 5 - NEUROCRINE BIOSCIENCES, INC.
Page 6 - NEUROCRINE BIOSCIENCES, INC.
Page 7 - Use of Estimates
Page 8 - Revenue Recognition.
Page 9 - Product Returns:
Page 10 - Licenses of Intellectual Property
Page 11 - AbbVie Inc. (AbbVie).
Page 12 - BIAL Portela CA, S.A. (BIAL).
Page 13 - in thousands
Page 14 - 4. FAIR VALUE MEASUREMENTS
Page 15 - in millions
Page 16 - 6. CONVERTIBLE SENIOR NOTES
Page 17 - in thousands
Page 18 - 7. NET INCOME (LOSS) PER SHARE
Page 19 - Stock Option Assumptions
Page 20 - 10. COMMITMENTS AND CONTINGENCIES
Page 21 - RESULTS OF OPERATIONS
Page 22 - Revenue Recognition
Page 23 - Government Rebates:
Page 24 - Milestone Payments
Page 25 - Convertible Debt
Page 26 - Research and Development
Page 27 - OFF-BALANCE SHEET ARRANGEMENTS
Page 28 - Changes in Internal Control over Financial Reporting
Page 29 - PART II: OTHER INFORMATION
Page 30 - We have no manufacturing capabilities. If third-party manufacturers of INGREZZA or any of our produc
Page 31 - *We depend on our current collaborators for the development and commercialization of our products an
Page 32 - *We do not and will not have access to all information regarding the products and product candidates
Page 33 - *If physicians and patients do not accept INGREZZA or any of our other products, or our sales and ma
Page 34 - *Because the development of our product candidates is subject to a substantial degree of technologic
Page 35 - *We have a history of losses and expect to increase our expenses for the foreseeable future, and we
Page 36 - *We license some of our core technologies and drug candidates from third parties. If we default on a
Page 37 - We could face liability if a regulatory authority determines that we are promoting INGREZZA, or any
Page 38 - Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of
Page 39 - *If we cannot raise additional funding, we may be unable to complete development of our product cand
Page 40 - Risks Related to Our Industry
Page 41 - We face intense competition, and if we are unable to compete effectively, the demand for our product
Page 42 - If we are unable to protect our intellectual property, our competitors could develop and market prod
Page 43 - If we fail to obtain or maintain orphan drug designation or other regulatory exclusivity for some of
Page 44 - *We face potential product liability exposure far in excess of our limited insurance coverage.
Page 45 - Our activities involve hazardous materials, and we may be liable for any resulting contamination or
Page 46 - EXHIBIT
Page 47 - SIGNATURES
Subdocument 2 - EX-3.1 - EX-3.1
Page 1 - I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED A
Page 2 - AND I DO HEREBY FURTHER CERTIFY THAT THE AFORESAID CERTIFICATES ARE THE ONLY CERTIFICATES ON RECORD
Page 3 - N/A
Page 4 - N/A
Page 5 - Limitation of Liability.
Page 6 - Number of Directors.
Page 7 - N/A
Page 8 - N/A
Page 9 - AGREEMENT AND PLAN OF MERGER
Page 10 - Merger
Page 11 - Certificate of Incorporation
Page 12 - Neurocrjne-Delaware Common Stock
Page 13 - Covenants of Neurocrine-Delaware
Page 14 - Registered Office.
Page 15 - N/A
Page 16 - EXHIBIT A
Page 17 - NEUROCRINE BIOSCIENCES
Page 18 - NEUROCRINE BIOSCIENCES
Page 19 - CERTIFICATE OF OWNERSHIP AND MERGER
Page 20 - N/A
Page 21 - CERTIFICATE OF AMENDMENT OF
Page 22 - CERTIFICATE OF AMENDMENT OF
Page 23 - NEUROCRINE BIOSCIENCES, INC
Subdocument 3 - EX-3.2 - EX-3.2
Page 1 - Exhibit 3.2
Page 2 - N/A
Page 3 - N/A
Page 4 - BYLAWS
Page 5 - NOTICE OF STOCKHOLDERS MEETINGS
Page 6 - QUORUM
Page 7 - STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A MEETING
Page 8 - LIST OF STOCKHOLDERS ENTITLED TO VOTE
Page 9 - RESIGNATION AND VACANCIES
Page 10 - FIRST MEETINGS
Page 11 - ADJOURNMENT
Page 12 - COMMITTEES
Page 13 - OFFICERS
Page 14 - CHAIRMAN OF THE BOARD
Page 15 - ASSISTANT SECRETARY
Page 16 - INDEMNIFICATION OF OTHERS
Page 17 - INSPECTION BY DIRECTORS
Page 18 - CHECKS; DRAFTS; EVIDENCES OF INDEBTEDNESS
Page 19 - SPECIAL DESIGNATION ON CERTIFICATES
Page 20 - CERTIFICATE OF ADOPTION OF BYLAWS
Page 21 - SPECIAL MEETING
Page 22 - NUMBER OF DIRECTORS
Page 23 - CERTIFICATE OF AMENDMENT OF
Page 24 - CERTIFICATE OF AMENDMENT OF
Page 25 - Number of Directors
Page 26 - NUMBER OF DIRECTORS
Page 27 - NUMBER OF DIRECTORS
Page 28 - FORUM FOR ADJUDICATION OF DISPUTES
Page 29 - NUMBER OF DIRECTORS
Subdocument 4 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 5 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 6 - EX-32 - EX-32
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer